Medical Management of Diabetic Vascular Disease

Noble J. , ed. Textbook of Primary Care Medicine. 3rd ed. St. Louis: Mosby; 2004.

Goldman L. , Ausiello D. , eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia: Saunders; 2004.

Woodman R.J. , Chew G.T. , Watts G.F. Mechanisms, significance, and treatment of vascular dysfunction in type 2 diabetes mellitus. Drugs 2005; 65: 31–74.

Moser M. , Sowers J.R. , editors. Clinical Management of Cardiovascular Risk Factors in Diabetes. 2nd ed. New York: Professional Communications, Inc., 2005.

Salehi M. , D'Alessio D.A. New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med. 2006; 73: 382–389.

DCCT. Diabetes control and complications trial. N Engl J Med. 1995; 75: 894–903.

UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylyreps or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UUPDS 33). Lancet. 1998; 352: 837–853.

United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UUPDS 38. UK Prospective Diabetes Study Group. BMT. 1998; 317: 703–713.

Hansson L. , Zanchetti A. , Carruthers S.G. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998; 351: 1755–1762.

Keech A. , Simes R.J. , Barter P. Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the Field study): randomized controlled trial. Lancet. 2005; 366: 1849–1865.

Patel A. , Chalmers J. , Poulter N. ADVANCE: actions in diabetic and vascular disease. J Hum Hypertens. 2005; 19: S27–S32.